TECH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TECH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.
Bio-Techne's net issuance of preferred for the three months ended in Dec. 2023 was $0 Mil. The number is 0, which means that Bio-Techne has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.
Bio-Techne's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.
The historical data trend for Bio-Techne's Net Issuance of Preferred Stock can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Bio-Techne's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.
Roeland Nusse | director | 473 TENNESSEE, PALO ALTO CA 94306 |
William Geist | officer: PRESIDENT, PROTEIN SCIENCES | 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821 |
Charles R. Kummeth | director, officer: Chief Executive Officer | 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213 |
Shane Bohnen | officer: SVP - General Counsel | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Brenda S. Furlow | officer: SVP - General Counsel | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
John L Higgins | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Robert V Baumgartner | director | 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416 |
Kim Kelderman | officer: Pres. Diagnostics & Genom | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Norman David Eansor | officer: SVP Biotech | 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120 |
James Hippel | officer: Chief Financial Officer | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Joseph D Keegan | director | C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089 |
Alpna Seth | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Julie L Bushman | director | 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214 |
Rupert Vessey | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Randolph C Steer | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.